Immunoregulatory pathways involved in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 21, Issue 9, 2015, Pages 2188-2193

  Fonseca Camarillo, Gabriela ^a   Yamamoto Furusho, Jesús K ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Cohn's disease; cytokines; immunoregulation; inflammatory bowel disease; ulcerative colitis

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 19; INTERLEUKIN 1BETA; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 24; INTERLEUKIN 26; INTERLEUKIN 35; INTERLEUKIN 37; INTERLEUKIN 6; INTERLEUKIN 9; STAT1 PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; IL10 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, HUMAN;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; TH9 CELL; ULCERATIVE COLITIS; HELPER CELL; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION;

HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84940948700     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000477     Document Type: Review

References (57)

1. Podolsky DK. Inflammatory bowel disease. N EnglJMed. 2002;347:417-429.
2. Fonseca-Camarillo G, Yamamoto-Furusho JK. Interleukins involved in inflammatory bowel disease as new therapeutic targets. Curr Immunol Rev. 2013;9:86-92.
3. Sartor BR. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390-407.
4. Xu XR, Liu CQ, Feng BS, et al. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2014;20:3255-3264.
5. Abraham C, Cho J. Mechanisms of disease inflammatory bowel disease. N Engl J Med. 2009;361:2066-2078.
6. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol. 1997;92:5S-11S.
7. Fonseca-Camarillo G, Furuzawa-Carballeda J, Llorente L, et al. IL-10-and IL-20 expressing epithelial and inflammatory cells are increased in patients with ulcerative colitis. J Clin Immunol. 2013;33:640-648.
8. Fonseca-Camarillo G, Furuzawa-Carballeda J, Granados J, et al. Expression of IL-19 and IL-24 in IBD patients: a cross-sectional study. Clin Exp Immunol. 2014;177:64-75.
9. Furuzawa-Carballeda J, Fonseca-Camarillo G, Lima G, et al. Indoleamine 2, 3-dioxygenase: expressing cells in inflammatory bowel disease-a cross-sectional study. Clin Dev Immunol. 2013;2013:278035.
10. Geremia A, Biancheri P, Allan P. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev. 2014;13:3-10.
11. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531-562.
12. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med. 2004;10:801-805.
13. Li X, Mai J, Virtue A, et al. IL-35 is a novel responsive anti-inflammatory cytokine-a new system of categorizing anti-inflammatory cytokines. PLoS One. 2012;7:e33628.
14. Ouyang W, Rutz S, Crellin NK, et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011;29:71-109.
15. Saruta M, Yu QT, Fleshner PR, et al. Characterization of FOXP3 + CD4+regulatory T cells in Crohn's disease. Clin Immunol. 2007;125: 281-290.
16. Wirtz S, Billmeier U, Mchedlidze T, et al, Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology. 2011;141:1875-1876.
17. Eastaff-Leung N, Mabarrack N, Barbour A, et al. Foxp3+regulatory T cells Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol. 2010;30:80-89.
18. Annunziato F, Cosmi L, Santarlasci V, et al. Phenotypic and functional features of human Th17. J Exp Med. 2007;204:1849-1861.
19. Yang M, Rui K, Wang S, Lu L. Regulatory B cells in autoimmune diseases. Cell Mol Immunol. 2013;10:122-132.
20. Vitale G, Mion F, Pucillo C. Regulatory B cells: evidence, developmental origin and population diversity. Mol Immunol. 2010;48:1-8.
21. Mizoguchi A, Mizoguchi E, Smith RN, et al. Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med. 1997; 186:1749-1756.
22. Sabat R. IL-10 family of cytokines. Cytokine Growth Factor Rev. 2010; 21:315-324.
23. Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol. 2008;121:1108-1111.
24. Gallagher G, Dickensheets H, Eskdale J, et al. Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). Genes Immun. 2000;1:442-450.
25. Liao YC, Liang WG, Chen FW, et al. IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol. 2002;169:4288-4297.
26. Wolk K, Witte E, Warszawska K, et al. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol. 2009;39:3570-3581.
27. Fickenscher H, Hör S, Küpers H, et al. The interleukin-10 family of cytokines. Trends Immunol. 2002;23:89-96.
28. Azuma YT, Matsuo Y, Kuwamura M, et al. Interleukin-19 protects mice from innate-mediated colonic inflammation. Inflamm Bowel Dis. 2010;16: 1017-1028.
29. Yamamoto-Furusho JK, Álvarez-León E, Fragoso JM, et al. Protective role of interleukin-19 gene polymorphisms in patients with ulcerative colitis. Hum Immunol. 2011;72:1029-1032.
30. Blumberg H, Conklin D, Xu WF, et al. Interleukin-20: discovery, receptor identification, and role in epidermal function. Cell. 2001;104:9-19.
31. Sa SM, Valdez PA, Wu J, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol. 2007; 178:2229-2240.
32. Kragstrup TW, Otkjaer K, Holm C, et al. The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy. Cytokine. 2008;41:16-23.
33. Chen WY, Cheng BC, Jiang MJ, et al. IL-20 is expressed in atherosclerosis plaques and promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26:2090-2095.
34. Li HH, Cheng HH, Sun KH, et al. Interleukin-20 targets renal mesan-gial cells and is associated with lupus nephritis. Clin Immunol. 2008; 129:277-285.
35. Hsu YH, Chang MS. Interleukin-20 antibody is a potential therapeutic agent for experimental arthritis. Arthritis Rheum. 2010;62:3311-3321.
36. Rich BE, Kupper TS. Cytokines: IL-20-a new effector in skin inflammation. Curr Biol. 2001;11:R531-R534.
37. Wolk K, Witte K, Witte E, et al. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol. 2008;83:1181-1193.
38. Zenewicz LA, Yancopoulos GD, Valenzuela DM, et al. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity. 2008;29:947-957.
39. Sugimoto K, Ogawa A, Mizoguchi E, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest. 2008; 118:534-544.
40. Andoh A, Zhang Z, Inatomi O, et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology. 2005;129:969-984.
41. Yamamoto-Furusho JK, Miranda-Pérez E, Fonseca-Camarillo G, et al. Colonic epithelial upregulation of interleukin 22 (IL-22) in patients with ulcerative colitis. Inflamm Bowel Dis. 2010;16:1823.
42. Kunz S, Wolk K, Witte E, et al. Interleukin IL-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol. 2006;15:991-1004.
43. Leng RX, Pan HF, Tao JH, et al. IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseases. Expert Opin Ther Targets. 2011;15:119-126.
44. Andoh A, Shioya M, Nishida A, et al. Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease. J Immunol. 2009;183:687-695.
45. Camarillo GF, Furuzawa-Carballeda J, Martínez-Benítez B, et al. Role of the interleukin 24 in patients with ulcerative colitis. Inflamm Bowel Dis. 2011;17:2209-2210.
46. Wolk K, Kunz S, Asadullah K, et al. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol. 2002;168:5397-5402.
47. Dambacher J, Beigel F, Zitzmann K. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut. 2009;58:1207-1217.
48. Niedbala W, Wei XQ, Cai B, et al. IL-35 is a novel cytokine with therapeutic effects against collagen induced arthritis through the expansion of regulatory T cells and suppression of Th17cells. Eur J Immunol. 2007;37:3021-3029.
49. Kochetkova I, Golden S, Holderness K, et al. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol. 2010;184:7144-7153.
50. Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014;507:366-370.
51. Kumar S, McDonnell PC, Lehr R, et al. Interleukin-1 family of four novel members of the identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem. 2000;275: 10308-10314.
52. Weidlich S, Bulau AM, Schwerd T, et al. Intestinal expression of the anti-inflammatory interleukin-1 homologue IL-37 in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2014;59:e18-26.
53. Quirk S, Agrawal DK. Immunobiology of IL-37: mechanism of action and clinical perspectives. Expert Rev Clin Immunol. 2014;10:1703-1709.
54. Ye L, Ji L, Wen Z, et al. IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity. J Transl Med. 2014;12:69.
55. Chen B, Huang K, Ye L, et al. Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity. J Transl Med. 2015;28:36-45.
56. Gerlach K, Hwang Y, Nikolaev A, et al. TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol. 2014; 15:676-686.
57. Leake I. TH9 cells might have a role in the pathogenesis of ulcerative colitis. Nat Rev Gastroenterol Hepatol. 2014;11:455.